Safety, pharmacokinetics and efficacy of IMCgp100, a first-in-class soluble TCR-antiCD3 bispecific t cell redirector with solid tumour activity: Results from the FIH study in melanoma.
用户4Ud7YDZAY51U
3天前
19
10
已关闭
DOI: 10.1200/jco.2016.34.15_suppl.3016
文献链接: http://ascopubs.org/doi/10.1200/JCO.2016.34.15_suppl.3016
其他信息:
出版社: American Society of Clinical Oncology (ASCO)
作者: Mark R. Middleton; Neil Matthew Steven; Thomas Jeff Evans; Jeffrey R. Infante; Mario Sznol; Clive Mulatero; Omid Hamid; Alexander Noor Shoushtari; William Shingler; Andy Johnson; Sanjay Patel; Debbie Parker; David Krige; Cheryl McAlpine; Christina Marie Coughlin; Namir J Hassan; Bent K Jakobsen; Philippa Corrie
